Interviews

Vamorolone (Agamree) is a first-in-class corticosteroid to treat Duchenne muscular dystrophy (DMD) in patients 2 years and older.

Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, shares 3 key recommendations to improve the accuracy and quality of drug pricing data.

Amy Shapiro, MD, medical director, Indiana Hemophilia and Thrombosis Center, continues her discussion on plasminogen deficiency type 1 by highlighting the recent FDA approval of plasminogen (Ryplazim; Kedrion Biopharma), the first treatment specifically indicated for this disorder.

In research presented at the American Thoracic Society 2024 International Conference, Benjafield and colleagues explored the treatment of sleep-disordered breathing with adaptive sero-ventilation (ASV) in opioid users with central sleep apnea (CSA).

Promising results from a phase 2 trial of ENV-101, a novel hedgehog inhibitor, showed improvement in lung function and reduction of fibrosis in patients with idiopathic pulmonary fibrosis, said Paul Frohna, MD, PhD, PharmD.

Chesahna Kindred, MD, MBA, FAAD, board-certified dermatologist, Kindred Hair & Skin Center, discusses ways to overcome barriers in clinical trials for diverse patients with psoriasis.

Debra Boyer, MD, MHPE, ATSF, chair of the American Thoracic Society (ATS) International Conference Committee, highlighted exciting keynote sessions on artificial intelligence in medicine, the history of intensive care units, and immigrant health care ahead of the ATS 2024 International Conference.

Kathryn Lindley, MD, FACC, Vanderbilt University Medical Center, shares what women can do to prioritize their heart health during National Women's Health Week and every week.

Mila Felder, MD, FACEP, emergency physician and vice president, Wellbeing for All Teammates, Advocate Health, discusses how to implement well-being into peer support within oncology care.

Amy Shapiro, MD, medical director of Indiana Hemophilia and Thrombosis Center, joined AJMC to shed light on a broadly overlooked disorder: plasminogen deficiency type-1.

Session speakers at the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research share their favorite parts of the conference.

Chris Pagnani, MD, medical director and founder of Rittenhouse Psychiatric Associates in Philadelphia, explains the importance of offering college students consistent care via telehealth while collaborating with their campus counseling centers.

Speakers at the 2024 American Urological Association (AUA) annual meeting highlighted the innovations and advancements that are pushing the field of urology forward.

New therapies being developed are moving into earlier lines of therapy, with the idea that most patients with early-stage prostate cancer will progress and need additional therapy later.

In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.

Phaedra Corso, PhD, associate vice president for research, Indiana University, discusses the importance of cost-effectiveness analysis in determining the feasibility and impact of public health interventions.

The Inflation Reduction Act (IRA) has potential to shift incentives for drug manufacturers and impact the amount of long-term evidence generated for approved drugs, said Julie Patterson, PharmD, PhD, senior director of research at the National Pharmaceutical Council.

William Padula, PhD, MSc, MS, assistant professor of pharmaceutical and health economics, University of California Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, discusses the benefits and advancements of cost-effectiveness analysis to improve decision-making and efficiency.

Michael Morse, MD, FACP, MHS, medical oncologist at Duke Cancer Center, explained gaps in care access and equity that must be addressed to ensure all patients with liver cancer can get the treatments they need.

In this interview, Chris Pagnani, MD, PC, emphasizes the benefits of telemedicine and its role in improving accessibility, particularly in the realm of mental health care.

Risk factors and prostate-specific antigen are both important when determining how to move forward with treatment, explained Angela Jia, MD, PhD, of University Hospitals and Case Western Reserve University School of Medicine.

Nancy Dreyer, PhD, MPH, FISE, chief scientific advisor to Picnic Health, shares some of the ways that direct-to-patient approaches have improved observational research.

There are increasingly more bladder-sparing strategies for patients with even aggressive bladder cancer, said Alexander Kutikov, MD, FACS, chair, Department of Urology, Fox Chase Cancer Center.

Kimberly Westrich, MA, of the National Pharmaceutical Council, explains how the 340B program is linked to increased drug spending and the hidden costs associated with it.

With more therapies available in bladder, kidney, and prostate cancers, collaboration among health care providers can help ensure patients are getting the most appropriate care for their type and stage of cancer, said Mary Dunn, MSN, NP-C, OCN, RN, of University of North Carolina.

Seth Berkowitz, MD, MPH, associate professor of medicine, University of North Carolina at Chapel Hill, discussed the challenges associated with developing a whole-person health index and potential solutions for the "wrong pocket" problem.

In 2024, the Asembia Specialty Pharmacy Summit celebrated 20 years and speakers highlighted the conversations around improving access and affordability taking place at the meeting.

Survey results from more than 1500 patients with diabetes revealed that 57% believed glucagon-like peptide-1 (GLP-1) weight loss drugs alone could be a "silver bullet" for managing their health goals.

Inma Hernandez, PharmD, PhD, professor at the University of California, San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, discussed the potential sources of savings associated with the Medicare Drug Price Negotiation Program.

In part 2 of our interview with Binod Dhakal, MD, he addresses how CARTITUDE-4 study findings help to advance the clinical understanding of ciltacabtagene autoleucel (cilta-cel) and the importance of vigilance and education on the treatment’s adverse effects.